-
Citi Downgrades Synergy Pharmaceuticals (SGYP) to Sell
-
Synergy Pharma (SGYP) Adds to Gains as Analyst Stokes Speculation Fire
-
Synergy Pharma (SGYP) May be Potential Target for Takeda - Bloomberg, Citing Citi
-
Citi Downgrades Synergy Pharmaceuticals (SGYP) to Neutral
-
Notable Analyst Rating Changes 8/25: (AAPL) (BAC) (RF) Upgraded; (BOKF) (SUNE) (GAS) Downgraded
-
Pre-Open Stock Movers 06/17: (SGYP) (KYTH) (QIHU) Higher; (DTEA) (AZUR) (EPE) Lower (more...)
-
Citi Starts Synergy Pharmaceuticals (SGYP) at Buy
-
Synergy Pharma (SGYP) Announces $90M Common Offering
-
Notable Analyst Rating Changes 09/25: (SWY) (GFI) (TIVO) Upgraded; (PAYX) (LEN) (ADP) Downgraded

